Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease

Health Technol Assess. 2003;7(3):1-67. doi: 10.3310/hta7030.
No abstract available

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Adult
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / economics*
  • Antirheumatic Agents / therapeutic use*
  • Cost-Benefit Analysis
  • Crohn Disease / drug therapy*
  • Crohn Disease / economics
  • Drug Costs
  • Drug Evaluation
  • Humans
  • Infliximab
  • Quality-Adjusted Life Years
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Infliximab